Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has received an average recommendation of “Buy” from the seven brokerages that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $35.00.

SUPN has been the topic of a number of research reports. Cantor Fitzgerald reissued a “buy” rating and issued a $31.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, March 1st. Jefferies Group LLC reaffirmed a “buy” rating and set a $33.00 price target on shares of Supernus Pharmaceuticals in a research note on Thursday, March 2nd. Zacks Investment Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 4th. Stifel Nicolaus raised their price target on shares of Supernus Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, April 3rd. Finally, Cowen and Company raised their price target on shares of Supernus Pharmaceuticals from $31.00 to $34.00 and gave the stock an “outperform” rating in a research note on Thursday, May 11th.

Shares of Supernus Pharmaceuticals (SUPN) traded down 1.28% during trading on Tuesday, reaching $38.65. 1,266,125 shares of the company’s stock were exchanged. The stock has a market cap of $1.94 billion, a P/E ratio of 20.79 and a beta of 1.76. Supernus Pharmaceuticals has a 12-month low of $17.25 and a 12-month high of $41.35. The company has a 50 day moving average of $35.55 and a 200 day moving average of $29.14.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $0.19 EPS for the quarter, missing the Zacks’ consensus estimate of $0.22 by $0.03. The business had revenue of $57.58 million during the quarter, compared to analyst estimates of $57.91 million. Supernus Pharmaceuticals had a net margin of 17.88% and a return on equity of 20.76%. Equities research analysts anticipate that Supernus Pharmaceuticals will post $1.08 EPS for the current year.

In related news, CFO Gregory S. Patrick sold 54,000 shares of the firm’s stock in a transaction that occurred on Monday, April 24th. The shares were sold at an average price of $32.37, for a total value of $1,747,980.00. Following the sale, the chief financial officer now directly owns 54,221 shares of the company’s stock, valued at $1,755,133.77. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, June 2nd. The stock was sold at an average price of $39.86, for a total transaction of $398,600.00. Following the completion of the sale, the vice president now directly owns 27,500 shares in the company, valued at $1,096,150. The disclosure for this sale can be found here. Insiders sold 83,806 shares of company stock worth $2,813,038 over the last three months. Corporate insiders own 6.70% of the company’s stock.

Several large investors have recently added to or reduced their stakes in SUPN. Bogle Investment Management L P DE boosted its stake in Supernus Pharmaceuticals by 59.0% in the fourth quarter. Bogle Investment Management L P DE now owns 263,184 shares of the specialty pharmaceutical company’s stock valued at $6,645,000 after buying an additional 97,673 shares in the last quarter. New York State Teachers Retirement System raised its position in Supernus Pharmaceuticals by 0.5% in the fourth quarter. New York State Teachers Retirement System now owns 77,035 shares of the specialty pharmaceutical company’s stock valued at $1,945,000 after buying an additional 400 shares during the last quarter. Pacad Investment Ltd. acquired a new position in Supernus Pharmaceuticals during the fourth quarter valued at approximately $124,000. Axiom International Investors LLC DE acquired a new position in Supernus Pharmaceuticals during the fourth quarter valued at approximately $2,522,000. Finally, Trexquant Investment LP acquired a new position in Supernus Pharmaceuticals during the fourth quarter valued at approximately $556,000. 92.17% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Supernus Pharmaceuticals Inc (SUPN) Receives $35.00 Average PT from Analysts” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/06/16/supernus-pharmaceuticals-inc-supn-receives-35-00-consensus-target-price-from-brokerages-updated.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Receive News & Stock Ratings for Supernus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.